Thirona Bio is developing a precision targeted drug platform to treat skin and lung fibrosis as well as certain cancers. The Company's therapies are organ-selective and locally acting inhibitors of TGF-β, the primary mediator of fibrosis. These products achieve high local drug levels and inhibit all TGF-β isoforms for maximum efficacy, with organ targeting & rapid drug metabolism to overcome the historical challenges of safely inhibiting TGF-β. • Thirona's lead program, TBIO-101, is designed to treat multiple fibrotic skin conditions including hypertrophic & keloid scarring, scleroderma and cutaneous squamous cell carcinoma, diseases with significant unmet medical need. • The FDA activated the IND for TBIO-101 after the drug demonstrated a remarkably clean pre-clinical safety profile and a dramatic reduction in profibrotic biomarkers of disease. First human dosing is expected in September. • The Company’s second product, TBIO-201, is being developed for fibrotic lung diseases.